Quest Diagnostics management check

DGX · Health Care · Health Care Services · CEO James E. Davis

Filings as of

67
Management score, ranked 218th of 487 · 25th of 60 in Health Care4 good · 2 to watch · 0 flaggedStrongest: clean books · Weakest: skin in the game · Best and worst run in Health Care →

Closest peers in Health Care Services

  1. 60CICigna80
  2. 126DVADaVita74
  3. 208ABBVAbbVie68
  4. 218DGXQuest Diagnostics67
  5. 223LHLabcorp66
  6. 305CVSCVS Health61

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$161Peers$148

    What $100 became since fiscal 2021

    6064th
    Detail

    $100 invested at the start of fiscal 2021 grew to $161, against $148 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    8045th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.61 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • n/a

    What does the CEO cost owners?

    Not enough data
    ——

    No pay or net income figure for the latest year.

  • Watch

    Do they own the stock?

    CEO stake ≈ 1.9 years of pay

    122,423 shares ≈ $29.7m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $23.7m sold

    4954th
    Detail

    The CEO holds 122,423 shares, directly or through trusts (unvested awards not counted): about 1.9 years of pay. Light activity: no buys, $23.7m sold in six months. 20 of 20 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 128m2025 · 113m

    Diluted shares +0.0% a year; flagged above +2%

    0%10%20%

    Stock pay 0.8% of revenue

    5035th
    Detail

    Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 0.8% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    3 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Stephen H. Rusckowski, James E. Davis

    6038th
    Detail

    CEOs in the pay table: Stephen H. Rusckowski, James E. Davis. 3 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 6, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$24.6m$49.2m$10020212022202320242025$161$148

Pay tied most to Adjusted Diluted Earnings Per Share

Other key measuresRevenuePatient Experience/Employee ExperienceCommunity Impact Goals

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025James E. Davis$15.5m$26.5m$3.3m$161$148—
2024James E. Davis$14.4m$24.3m$3.0m$137$129—
2023James E. Davis$12.7m$9.4m$2.9m$123$126—
2022Stephen H. Rusckowski, James E. Davis$15.7m$12.7m$3.4m$136$124—
2021Stephen H. Rusckowski$14.6m$49.2m$3.4m$148$126—

Insiders and the CEO's stakeQuiet

CEO and President
J. E. Davis
Shares held
122,423
At that filing's price
≈ $29.7m
Latest Form 4
Sep 1, 2026

Light activity: no buys, $23.7m sold in six months. 20 of 20 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldMichael E PrevoznikSVP & General Counsel · 10b5-1 plan$5.5mAug 28, 2026
  • SoldCatherine T. DohertyExecutive Vice President · 10b5-1 plan$5.5mNov 3, 2026
  • SoldJ. E. DavisCEO and President · 10b5-1 plan$4.4mSep 1, 2026
  • SoldMichael J DeppeSVP, Corp. Controller & CAO · 10b5-1 plan$3.1mNov 13, 2026

Leadership and governance on file

20222023202420252026Leadership 14Votes 5
All 14 filings

Latest shareholder vote results: May 21, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $6.1bn returned to owners in buybacks and dividends, 108% of net income, and $409.0m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$1.3bn$2.5bn20212022202320242025Shares128m118m113m113m113m
Show the figures
Fiscal year20212022202320242025
Revenue$10.8bn$9.9bn$9.3bn$9.9bn$11.0bn
Net income$2.0bn$946.0m$854.0m$871.0m$992.0m
Stock-based pay$79.0m$77.0m$77.0m$88.0m$88.0m
Buybacks$2.2bn$1.4bn$275.0m$151.0m$450.0m
Dividends$309.0m$305.0m$314.0m$331.0m$353.0m
Diluted shares128m118m113m113m113m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.